Invest now
Jagsonpal Pharmaceuticals share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹229.90(-1.10%)August 11, 2026 15:24:29 PM IST
- NSE
- BSE
- Vol : 54.51 K (NSE + BSE)Last 20 day avg : 833.32 K
Jagsonpal Pharmaceuticals is trading -1.10% lower at Rs 229.90 as compared to its last closing price. Jagsonpal Pharmaceuticals has been trading in the price range of 233.95 & 229.35. Jagsonpal Pharmaceuticals has given 20.95% in this year & -1.02% in the last 5 days. Jagsonpal Pharmaceuticals has TTM P/E ratio 35.01 as compared to the sector P/E of 32.78.The company posted a net profit of 13.19 Crores in its last quarter.Listed peers of Jagsonpal Pharmaceuticals include Aurobindo Pharma (-0.24%), Neuland Laboratories (3.66%), Pfizer (0.70%).The Mutual Fund holding in Jagsonpal Pharmaceuticals was at 0.11% in 30 Sep 2024. The MF holding has - from the last quarter. The FII holding in Jagsonpal Pharmaceuticals was at 2.30% in 30 Jun 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 12 Aug 2026, 01:49 AM IST
- BetaLow volatility0.43Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.03The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldHigher than industry1.72Annual dividends as a percentage of the stock price.
- PEG RatioIndicates overvaluation2.22The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Jagsonpal Pharmaceuticals News
Jagsonpal Pharmaceuticals Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Aurobindo Pharma | 1,642.00 | -0.24 | 94,477.05 | 25.52 | 2.39 | 0.26 | 2.89 |
| Neuland Laboratories | 23,005.80 | 3.66 | 29,375.49 | 66.08 | 12.97 | 0.18 | 13.90 |
| Pfizer | 4,909.45 | 0.70 | 22,459.62 | 27.60 | 4.98 | 1.64 | 0.86 |
| Unichem Laboratories | 574.30 | 13.06 | 4,035.85 | 54.87 | 1.54 | - | 2.40 |
| Themis Medicare | 114.00 | 3.92 | 1,051.86 | 651.23 | 2.62 | 0.44 | 5.48 |
Jagsonpal Pharmaceuticals Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-07-29 | Quarterly Results |
| 2026-04-27 | Audited Results & Final Dividend |
| 2026-03-12 | Buy Back of Shares |
| 2026-01-21 | Quarterly Results |
| 2025-11-03 | Quarterly Results |
About the company Jagsonpal Pharmaceuticals
- IndustryMajor Drugs
- ISININE048B01035
- BSE Code507789
- NSE CodeJAGSNPHARM
Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its Gynaecology products include Divatrone, Endoreg, Cystelia-M, Fibristone, Yuliprist, Deereg, and Lycored Softgel. Its Orthopaedics products include JP Tone Up, Metadec 50 Injection, Metadec 25 Injection, Indocap SR, and Indocap, Colla-2. Its other products include Equirex, Doxypal DR-L, JP Tone Syrup, and Lycored Syrup.
Jagsonpal Pharmaceuticals Share Price FAQs
Jagsonpal Pharmaceuticals is trading at 229.90 as on Tue Aug 11 2026 09:54:29. This is -1.10% lower as compared to its previous closing price of 232.45.
The market capitalization of Jagsonpal Pharmaceuticals is 1505.68 Cr as on Tue Aug 11 2026 09:54:29.
The 52 wk high for Jagsonpal Pharmaceuticals is 264.65 whereas the 52 wk low is 154.90
Jagsonpal Pharmaceuticals can be analyzed on the following key metrics -
- TTM P/E: 35.01
- Sector P/E: 32.78
- Dividend Yield: 1.72%
- D/E ratio: -
Jagsonpal Pharmaceuticals reported a net profit of 43.08 Cr in 2026.
The Mutual Fund Shareholding was 0.11% at the end of 30 Sep 2024.
Quick Links
EQUITY QUICK LINKS
Jagsonpal Pharmaceuticals QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.